The main goal of the Pharmacogenomics Lab focuses on the study of germline and somatic variants (polymorphisms and mutations) in complex diseases in order to identify markers associated to disease risk and drug treatment response. Focusing on personalized medicine, the interest of our group is to define genetic factors responsible for the phenotypic variability accompanying different disease models. Molecular biology methodologies are employed in the laboratory to study specific genes encoding drug metabolism and transport enzymes, as well as genes involved in the DNA damage response, apoptosis and proliferation mediated by the p53 signaling pathway. Massive genomic analysis of variants is also undertaken through DNA microarray platforms or whole exome sequencing to identify disease-specific genetic markers and/or pharmacogenes.

Chair: Ariela Freya Fundia, MSc, PhD
Associated investigator – CONICET


Research lines
Awards and recognitions